Health Care [ 9/12 ] | Biotechnology [ 38/73 ]
NASDAQ | Common Stock
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.
The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types.
The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University.
The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.29 Decreased by -3.57% | -0.36 Increased by +19.44% |
| Mar 19, 25 | -0.42 Increased by +10.64% | -0.35 Decreased by -20.00% |
| Nov 7, 24 | -0.40 Increased by +6.98% | -0.40 Decreased by -1.27% |
| Aug 13, 24 | -0.46 Increased by +4.17% | -0.48 Increased by +4.17% |
| May 14, 24 | -0.28 Increased by +37.78% | -0.51 Increased by +45.10% |
| Mar 21, 24 | -0.47 Increased by +11.32% | -0.48 Increased by +2.08% |
| Nov 9, 23 | -0.43 Increased by +25.86% | -0.50 Increased by +14.00% |
| Aug 7, 23 | -0.48 Increased by +21.31% | -0.49 Increased by +2.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 1.22 M Decreased by -76.83% | -11.04 M Decreased by -2.12% | Decreased by -903.44% Decreased by -340.73% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -15.94 M Increased by +10.99% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 1.14 M Decreased by -54.87% | -15.18 M Increased by +6.65% | Decreased by -1.33 K% Decreased by -106.83% |
| Jun 30, 24 | 1.27 M Decreased by -11.03% | -21.20 M Decreased by -17.38% | Decreased by -1.66 K% Decreased by -31.92% |
| Mar 31, 24 | 5.27 M Increased by +188.83% | -10.81 M Increased by +30.45% | Decreased by -204.99% Increased by +75.92% |
| Dec 31, 23 | 2.09 M Increased by +48.05% | -17.90 M Increased by +5.55% | Decreased by -857.01% Increased by +36.20% |
| Sep 30, 23 | 2.53 M Increased by +19.70% | -16.26 M Increased by +25.29% | Decreased by -643.08% Increased by +37.58% |
| Jun 30, 23 | 1.43 M Increased by +2.87% | -18.06 M Increased by +18.91% | Decreased by -1.26 K% Increased by +21.18% |